Loading...
A single dose of the 17D live-attenuated yellow fever virus (YFV) vaccine provides lifelong immunity, but the vaccine supply can be unreliable, and the World Health Organization recommends using fractional vaccine doses when outbreaks occur amid shortages. Evidence is needed on the efficacy of these lower doses from different vaccine manufacturers and in different populations, however. In a noninferiority trial conducted in Kenya and Uganda, 480 adult volunteers aged 18 to <60 years and without prior YFV infection or immunization were randomized to receive the 17D-204 YFV vaccine, manufactured by the Institut Pasteur de Dakar, at either the standard dose of 13,803 IU or at 1000, 500, or 250 IU. The primary outcome was seroconversion at 28 d…